ʻO ka lymphoma B-cell nui i hoʻolaha ʻia (DLBCL), NOS, ʻano GCB, lymphoma ʻōnaehana nerve waena mua-01

I Dekemaba 2019, ua hoʻomaka ʻo Mr. Wang, he kumu mai ka Hikina ʻĀkau o Kina, e ʻike i nā poʻo ʻeha. I ka lā 19 o Dekemaba, 2019, ua hōʻike nā hoʻokolohua diagnostic i kēia mau mea: Ua hōʻike ʻo PET-CT i kahi aka density me ka hoʻonui nui ʻia o ka metabolism FDG ma ka lobe frontal hema a me ka ʻāpana kuli corpus callosum (ma kahi o 3.4 * 1.9 cm, SUVmax=34.4). Ua hōʻoia ka biopsy a me ka immunohistochemistry i ka diffuse large B-cell lymphoma (DLBCL, NOS, GCB subtype), me kahi immunophenotype e hōʻike ana iā Ki67(50%+), CD19(+), CD20(+), PAX5(+), CD79(+), MUM1(+), BCL(+), CD10(-/+), CD2(minor+). Ua hōʻike ka loiloi wai Cerebrospinal i 6% mau cell lymphoid immature me ka loli morphological. ʻO ka maʻi i hōʻike ʻia he lymphoma ʻōnaehana nerve waena mua (DLBCL, GCB subtype).

Ma hope o ka noiʻi ʻana i nā koho lapaʻau ma ka pūnaewele, ua aʻo ʻo Mr. Wang e pili ana i nā hiki ke immunotherapy BIOOCUS Medical Group a ua ʻimi koke i ko lākou ʻike. Ma hope o nā hoʻokolohua kino piha a me ka nānā pono ʻana e ka hui loea o ka haukapila, ua hoʻoholo ʻia e komo ʻo Mr. Wang i kahi hoʻokolohua lapaʻau no ka lāʻau lapaʻau CART, me ka hoʻohana pono ʻana i nā cell CD19 CART. Ua loaʻa iā ia ka hoʻokomo ʻana o nā cell CD19 CAR-T autologous ma ʻApelila 24, 2023. Ma Iulai 30, 2023, ua loiloi ʻia ua loaʻa iā ia ke kala piha (CR) a ua hoʻi hou i ke ola maʻamau.